Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | $7.36B+83.4% |
| Revenue (ttm) | $3.20B |
| Net Income | $133.30M |
| EPS | $0.40 |
| Shares Out | 348.41M |
| PE Ratio | 52.80 |
| Forward PE | 17.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,672,746 |
| Open | $21.25 |
| Previous Close | $21.39 |
| Day's Range | $21.07 - $21.70 |
| 52-Week Range | $11.71 - $22.13 |
| Beta | 1.21 |
| Analysts | none |
| Price Target | $24.29(+14.99%) |
| Earnings Date | Nov 3, 2026 |
About AMRX
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating AMRX in the last 3 months, one vote each. Issuer-paid research is not counted.
$AMRX stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of AMRX by members of U.S. Congress
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | May 29, 2019 |
| Gilbert CisnerosHouse / D | Sale$1.00K – $15.00K | May 29, 2019 |
| Gilbert Ray CisnerosHouse / D | Sale$1.00K – $15.00K | May 28, 2019 |
| Josh GottheimerHouse / D | Sale$1.00K – $15.00K | May 24, 2019 |
Recently reported changes in AMRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AMRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AMRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AMRX Revenue by Segment
| Affordable Medicines | $547.11M | 63.42% |
| AvKARE | $165.31M | 19.16% |
| Specialty | $150.26M | 17.42% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AMRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AMRX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from AMRX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Amneal secured European regulatory approval for Adcomfo biosimilar, a concrete positive business achievement signaling market expansion.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BCUS | Bancreek U.S. Large Cap ETF | 4.43% |
| PJP | Invesco Pharmaceuticals ETF | 3.65% |
| ASCE | Allspring SMID Core ETF | 3.28% |
| CSMD | Congress SMID Growth ETF | 2.79% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 2.51% |
| BCGS | Bancreek Global Select ETF | 2.23% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 2.11% |
| SRHQ | SRH U.S. Quality GARP ETF | 1.84% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 1.77% |
| XSMO | Invesco S&P SmallCap Momentum ETF | 1.75% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 1.39% |
| RSMC | Rockefeller U.S. Small-Mid Cap ETF | 1.32% |
Weight is the stock’s share of each fund’s holdings.
